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Sir,
We appreciate the detailed critical analysis of our work by
Maioli and Fortino, who have also been investigating the actions of
PTHRP in MCF7 cells. The authors make a number of observations
and criticisms of our work, to which we are glad to have the
opportunity to respond.
The first point raised relates to our discussion of some work
published by Falzon and Du (2000) regarding intracrine actions of
PTHRP. It is true to say we considered that, because their data
showing the intracrine effect required overexpression of PTHRP,
such a mechanism was unlikely to operate in our system, in which
we showed that endogenous PTHRP production was extremely
low. We did not, however, question the physiological relevance of
the Falzon group’s findings and indeed suggested that it would be
interesting to test for the presence of intracrine and autocrine
activity in cells overexpressing both ligand and receptor.
The second point relates to the dose-responsiveness of MCF-7
cells to PTHRP. Maioli and Fortino’s results show that, at PTHRP
concentrations approximately five-fold higher than the highest dose
employed in our study, PTHRP exerts an inhibitory effect on
proliferation. While we agree that this is an interesting difference
with our work, it represents a difference in experimental conditions
employed and not, as implied, a difference in cellular responsive-
ness to PTHRP. Indeed, since Maoli and Fortino do not show a dose
response experiment, it is unclear how their cells would respond to
125nM PTHRP. On the same point, as stated in our paper, we did
not detect any PTHRP-induced Ca
2þ signal in parental MCF-7 cells
treated with 125nM PTHRP, but did not examine this at the higher
ligand concentrations employed by Maioli and Fortino. We suggest,
therefore, that there is no basis for their comment about the likely
loss of this pathway in our cells. However, in the light of the data
shown by Maioli and Fortino, it would clearly be interesting to
conduct a more detailed dose–response analysis of the effects of
PTHRP on mitogenesis in MCF-7 cells.
The third point raised by Maioli and Fortino alludes to our
finding of an increased sensitivity to growth factors in cells
overexpressing the PTH1R. We were, of course, aware of the vast
literature on tyrosine kinase receptor (TKR) transactivation by G
protein-coupled receptors and did not claim to be making a novel
observation in that respect. We merely report the phenomenon,
which we believe is interesting, but do not, at this stage, have
substantive experimental evidence concerning its underlying
mechanism. We can say however that our unpublished data
indicate that the sensitivity observation is not due to TKR
transactivation, and appears instead to involve a synergistic
interaction of signalling pathways downstream of the two
receptors.
The final point relates to the effects of forskolin on proliferation;
our results indicate a positive effect of forskolin, whereas Maoli
and Fortino report a negative effect. As stated in our paper,
different concentrations of forkolin that lead to differences in both
the peak level of cAMP induced as well as its temporal kinetics can
affect cellular outcome. The promitogenic effects we observed were
in reponse to 100nM drug whereas Maioli and Fortino saw
antiproliferative effects at 100mM forskolin. We suggested, on this
same point, that such a phenomenon could also explain the
apparent contradictory effects of expressing a constitutively active
allele of Gs in MCF-7 cells (Chen et al., 1998).
In summary, although there appear to be a number of
differences between aspects of our work and the preliminary
findings of Maioli and Fortino, most of these appear to be based on
differences in experimental approach. Therefore, it is not
surprising that some divergent results have emerged. We would
like to emphasise that the aim of our work was, in essence, to
determine the effects of increased levels of PTH1R expression in
breast cancer cells, aims which, though overlapping, are clearly
divergent from those that could be addressed by the Maioli and
Fortino study.
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